Methylprednisolone sodium succinate and Paraplegia - a phase IV clinical study of FDA data
Paraplegia is found among people who take Methylprednisolone sodium succinate, especially for people who are male, 50-59 old.
The phase IV clinical study analyzes which people take Methylprednisolone sodium succinate and have Paraplegia. It is created by eHealthMe based on reports of 13,080 people who have side effects when taking Methylprednisolone sodium succinate from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
13,080 people reported to have side effects when taking Methylprednisolone sodium succinate.
Among them, 7 people (0.05%) have Paraplegia.
What is Methylprednisolone sodium succinate?
Methylprednisolone sodium succinate has active ingredients of methylprednisolone sodium succinate. eHealthMe is studying from 13,090 Methylprednisolone sodium succinate users for its effectiveness, alternative drugs and more.
What is Paraplegia?
Paraplegia (paralysis of the legs and lower body) is found to be associated with 911 drugs and 500 conditions by eHealthMe.
Number of Methylprednisolone sodium succinate and Paraplegia reports submitted per year:
Gender of people who have Paraplegia when taking Methylprednisolone sodium succinate *:
- female: 42.86 %
- male: 57.14 %
Age of people who have Paraplegia when taking Methylprednisolone sodium succinate *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 16.67 %
- 40-49: 16.67 %
- 50-59: 50.0 %
- 60+: 16.67 %
Common side effects people have besides Paraplegia *:
- Urinary Retention (the inability to completely or partially empty the bladder): 2 people, 28.57%
- Weakness: 1 person, 14.29%
- Arteriovenous Fistula: 1 person, 14.29%
- Blindness: 1 person, 14.29%
- Cranial Nerve Disorder (impaired functioning of one of the twelve cranial nerves): 1 person, 14.29%
- Fatigue (feeling of tiredness): 1 person, 14.29%
- Fluid Retention (an abnormal accumulation of fluid in the blood): 1 person, 14.29%
- Gait Disturbance: 1 person, 14.29%
- Hypoacusis (loss of hearing): 1 person, 14.29%
- Lymphopenia (an abnormally low level of lymphocytes in the blood): 1 person, 14.29%
Common conditions people have *:
- Myelopathy (any neurologic deficit related to the spinal cord): 2 people, 28.57%
- Myelitis (infection or the inflammation of white matter or gray matter of spinal cord which is a part of central nervous system): 2 people, 28.57%
- Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 1 person, 14.29%
- Spondyloarthropathy (any joint disease of the vertebral column): 1 person, 14.29%
- Myelitis Transverse (a neurological condition consisting of an inflammatory process of the spinal cord): 1 person, 14.29%
* Approximation only. Some reports may have incomplete information.
Do you take Methylprednisolone sodium succinate and have Paraplegia?Check whether Paraplegia is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Lee, Y. J., & Park, K. , "Secondary Raynaud’s Phenomenon and Skin Necrosis of Toes in the Paraplegic Patient with Hypertension", Drug safety-case reports, 2018 Jan .
How severe was Paraplegia and when was it recovered:
Expand to all the drugs that have ingredients of methylprednisolone sodium succinate:
Alternative drugs to, pros and cons of Methylprednisolone sodium succinate:
- Methylprednisolone sodium succinate (13,090 reports)
Common Methylprednisolone sodium succinate side effects:
- High blood pressure: 1,528 reports
- Fatigue (feeling of tiredness): 1,213 reports
- Rashes (redness): 1,132 reports
- Headache (pain in head): 1,083 reports
- Drug ineffective: 1,065 reports
- Fever: 1,014 reports
- Pneumonia: 933 reports
Browse all side effects of Methylprednisolone sodium succinate:a b c d e f g h i j k l m n o p q r s t u v w x y z
Paraplegia treatments and more:
- Paraplegia (3,662 reports)
COVID vaccines that are related to Paraplegia:
- Paraplegia in Moderna COVID Vaccine
- Paraplegia in Pfizer BioNTech Covid Vaccine
- Paraplegia in Johnson and Johnson Covid Vaccine
Common drugs associated with Paraplegia:
- Methotrexate: 244 reports
- Prednisone: 239 reports
- Metformin: 159 reports
- Avonex: 157 reports
- Morphine: 153 reports
- Fentanyl: 142 reports
- Lyrica: 132 reports
- Cytarabine: 130 reports
- Heparin: 124 reports
- Omeprazole: 117 reports
All the drugs that are associated with Paraplegia:
- Paraplegia (911 drugs)
Common conditions associated with Paraplegia:
- Multiple sclerosis: 386 reports
- Pain: 196 reports
- Multiple myeloma: 123 reports
- Rheumatoid arthritis: 118 reports
- High blood pressure: 113 reports
All the conditions that are associated with Paraplegia:
- Paraplegia (500 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on methylprednisolone sodium succinate (the active ingredients of Methylprednisolone sodium succinate) and Methylprednisolone sodium succinate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Prilosec and Haematocrit Decreased - now
- Trusopt and Lichen Planus - a second ago
- Zanaflex and Strabismus - 2 seconds ago
- Carisoprodol and Clostridium Difficile Colitis - 3 seconds ago
- Hydroxyzine Pamoate and Colecalciferol drug interaction - 5 seconds ago
- Quinine Sulfate and Acute Hepatic Failure - 5 seconds ago
- Metronidazole and Prevymis drug interaction - 9 seconds ago
- Myrbetriq and Kadian drug interaction - 9 seconds ago
- Rezurock and Novolog drug interaction - 12 seconds ago
- Lupron Depot-4 and Vitamin E drug interaction - 13 seconds ago